GlassScriptPhysician profile
Flavius Dragila
NPI 1619107216
$1,174.97
in general payments reported to CMS, 2019-2025
15 companies · $42.48 in 2025
The $42.48 reported for 2025 was less than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $65.02 · 2021: $13.87 · 2022: $147 · 2023: $369 · 2024: $184 · 2025: $42.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $595.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $237.53 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $190.97 | 2019-2024 | Lifevest |
| Abbvie INC. | $122.83 | 2022-2025 | Dalvance, Teflaro |
| Merck Sharp & Dohme LLC | $101.08 | 2019-2023 | Dificid |
| Allergan, INC. | $93.40 | 2019 | |
| Mallinckrodt Hospital Products INC. | $92.64 | 2022-2024 | Terlivaz |
| Janssen Pharmaceuticals, INC | $61.98 | 2020-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.27 | 2019-2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $56.22 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $47.55 | 2019 | |
| La Jolla Pharmaceutical Company | $40.70 | 2023 | Xerava |
| Vifor Pharma, INC. | $23.00 | 2019 | |
| Melinta Therapeutics, LLC | $19.46 | 2019 | |
| Daxor Corporation | $16.83 | 2023 | Bva-100 |
| Astrazeneca Pharmaceuticals LP | $11.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Flavius Dragila listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.